JS 001

Drug Profile

JS 001

Alternative Names: Anti-PD1 monoclonal antibody - Shanghai Junshi; JS001

Latest Information Update: 15 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Shanghai Junshi Biosciences
  • Developer Fudan University; Peking University; Shanghai Junshi Biosciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Malignant melanoma
  • Phase I/II Gastric cancer; Head and neck cancer; Nasopharyngeal cancer; Oesophageal cancer
  • Phase I Breast cancer; Lymphoma; Neuroendocrine tumours; Renal cancer; Solid tumours; Urogenital cancer

Most Recent Events

  • 18 Aug 2017 Fudan University plans a phase I trial for Breast cancer (First-line therapy, Combination therapy, Metastatic therapy) (NCT03251313)
  • 06 Jun 2017 Efficacy data from a phase I trial in Renal cancer, Malignant melanoma and Urogenital cancer reported at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 02 Jun 2017 Adverse events data from a phase I trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top